{
    "2018-07-01": [
        [
            {
                "time": "",
                "original_text": "药明康德刚来A股又要去H股 为啥高破发率还蜂拥至港 连续下跌",
                "features": {
                    "keywords": [
                        "药明康德",
                        "A股",
                        "H股",
                        "破发率",
                        "连续下跌"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药独角兽再谋港股上市 药明康德拟发行H股",
                "features": {
                    "keywords": [
                        "医药",
                        "独角兽",
                        "港股",
                        "药明康德",
                        "发行H股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "复星医药：将陆续上市新药 重磅产品利妥昔单抗即将推出",
                "features": {
                    "keywords": [
                        "复星医药",
                        "新药",
                        "利妥昔单抗",
                        "重磅产品"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "复星医药：并购方面更注重战略能力的获取",
                "features": {
                    "keywords": [
                        "复星医药",
                        "并购",
                        "战略能力"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "复星医药：现阶段仿制药贡献主要现金流 创新药占比将越来越高",
                "features": {
                    "keywords": [
                        "复星医药",
                        "仿制药",
                        "现金流",
                        "创新药"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【高管面对面】复星医药：创新驱动 迈向国际一流医疗健康产业集团",
                "features": {
                    "keywords": [
                        "复星医药",
                        "创新驱动",
                        "国际一流",
                        "医疗健康"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}